Analysis of 3-year national reimbursement application data on etanercept and efalizumab for psoriasis
R.J.B. Driessen,
R.J.B. Driessen
Department of Dermatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6525 GL Nijmegen, the Netherlands
Search for more papers by this author E.M.G.J.
De Jong,
E.M.G.J.
De Jong
Department of Dermatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6525 GL Nijmegen, the Netherlands
Search for more papers by this author M.A.
De Rie,
M.A.
De Rie
Department of Dermatology, Academic Medical Centre, University of Amsterdam, the Netherlands
Search for more papers by this author G.W. Salemink,
G.W. Salemink
Zorgverzekeraars Nederland, Zeist, the Netherlands
Search for more papers by this author P.C.M.
Van De Kerkhof,
P.C.M.
Van De Kerkhof
Department of Dermatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6525 GL Nijmegen, the Netherlands
Search for more papers by this author
R.J.B. Driessen,
R.J.B. Driessen
Department of Dermatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6525 GL Nijmegen, the Netherlands
Search for more papers by this author E.M.G.J.
De Jong,
E.M.G.J.
De Jong
Department of Dermatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6525 GL Nijmegen, the Netherlands
Search for more papers by this author M.A.
De Rie,
M.A.
De Rie
Department of Dermatology, Academic Medical Centre, University of Amsterdam, the Netherlands
Search for more papers by this author G.W. Salemink,
G.W. Salemink
Zorgverzekeraars Nederland, Zeist, the Netherlands
Search for more papers by this author P.C.M.
Van De Kerkhof,
P.C.M.
Van De Kerkhof
Department of Dermatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6525 GL Nijmegen, the Netherlands
Search for more papers by this author
First published: 21 August 2008
No abstract is available for this article.
References
- 1
Fredriksson T,
Pettersson U.
Severe psoriasis – oral therapy with a new retinoid.
Dermatologica
1978; 157: 238–44.
- 2
Wakkee M,
Thio HB,
Spuls PI
et al.
Evaluation of the reimbursement criteria for biological therapies for psoriasis in the Netherlands.
Br J Dermatol
2008; 158: 1159–61.
- 3
Woolacott N,
Hawkins N,
Mason A
et al.
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Health Technol Assess
2006; 10: 1–233, i–iv.
- 4
Driessen RJ,
Berends MA,
Boezeman JB
et al.
Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome.
Br J Dermatol
2008; 158: 1098–106.
- 5
De Groot M,
Appelman M,
Spuls PI
et al.
Initial experience with routine administration of etanercept in psoriasis.
Br J Dermatol
2006; 155: 808–14.
- 6
Gisondi P,
Girolomoni G.
Biologic therapies in psoriasis: a new therapeutic approach.
Autoimmun Rev
2007; 6: 515–19.
